UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/539,169	06/14/2005	Frank Brady	PZ02108	9282
36335 GE HEALTHC	7590 11/20/200 <b>ARE, INC</b> .	EXAMINER		
IP DEPARTMENT 101 CARNEGIE CENTER			PERREIRA, MELISSA JEAN	
PRINCETON, NJ 08540-6231		ART UNIT	PAPER NUMBER	
			1618	
			MAIL DATE	DELIVERY MODE
			11/20/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/539,169	BRADY ET AL.
Office Action Summary	Examiner	Art Unit
	MELISSA PERREIRA	1618
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet with the	correspondence address
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory perion.  - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the main earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATIO 1.136(a). In no event, however, may a reply be ti ord will apply and will expire SIX (6) MONTHS from tute, cause the application to become ABANDON	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
1) ☐ Responsive to communication(s) filed on 14 2a) ☐ This action is <b>FINAL</b> . 2b) ☐ The 3) ☐ Since this application is in condition for allow closed in accordance with the practice under	nis action is non-final. vance except for formal matters, pr	
Disposition of Claims		
4) ☐ Claim(s) 4 and 5 is/are pending in the application 4a) Of the above claim(s) is/are withdrest is/are allowed.  5) ☐ Claim(s) is/are allowed.  6) ☐ Claim(s) 4 and 5 is/are rejected.  7) ☐ Claim(s) is/are objected to.  8) ☐ Claim(s) are subject to restriction and Application Papers	rawn from consideration.	
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) and applicant may not request that any objection to the	ccepted or b) objected to by the ne drawing(s) be held in abeyance. Se	ee 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the		•
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure * See the attached detailed Office action for a list	nts have been received. nts have been received in Applica iority documents have been receiv au (PCT Rule 17.2(a)).	tion No red in this National Stage
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date	4)  Interview Summar Paper No(s)/Mail D 5)  Notice of Informal 6)  Other:	oate

Application/Control Number: 10/539,169 Page 2

Art Unit: 1618

## **DETAILED ACTION**

Claims 4 and 5 are pending in the application. Claims 1-3 and 6-14 were cancelled in the amendment filed 7/14/09. Any objections and/or rejections from previous office actions that have not been reiterated in this office action are obviated.

## **New Grounds of Rejection**

## Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. Claims 4 and 5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Luthra et al. (US 2004/0236085) in view of Stevens et al. (WO01/14354) and Scheler (US 4,540,648).
- 3. Luthra et al. (US 2004/0236085) discloses a solid-phase process for the production of radiolabelled tracers which are suitable for use as Positron Emission Tomography (PET) radiotracers (abstract; p6, [0099]). The process for the production of radiolabelled tracers comprise a.) treatment of a resin-bound precursor, SOLID SUPPORT-LINKER-I<sup>+</sup>-TRACER Y<sup>-</sup>, with <sup>18</sup>F<sup>-</sup> to produce the labeled tracer, <sup>18</sup>F-TRACER; b.) removal of excess <sup>18</sup>F<sup>-</sup> by ion-exchange chromatography; c.) removal of any protecting groups; d.) removal of organic solvent; e.) formulation of the resultant <sup>18</sup>F-TRACER as an aqueous solution (p1, [0004-0006], [0008-0015]; p6, [0081]). The

Art Unit: 1618

SUPPORT-LINKER (i.e. polystyrene) of the disclosure encompasses the SUPPORT-LINKER of the instant claims and Y<sup>-</sup> (i.e. triflate) encompasses the Y<sup>-</sup> of the instant claims. Luthra et al. does not disclose a benzothiazole TRACER.

- 4. Stevens et al. (WO01/14354) discloses <sup>18</sup>F-substituted benzothiazoles for use in PET (p5, lines 3-17).
- 5. Scheler (US 4,540,648) discloses a benzothiazole/light sensitive compound linked to a solid support/film (i.e. polystyrene) via a coupler component (abstract; column 3, lines 25+; column 7, lines 5-11 and 60-66; claim 1). The polystyrene solid support encompasses the solid support of the disclosure as evidenced in the specification p6, lines 1-8.
- 6. At the time of the invention it would have been obvious to one ordinarily skilled in the art to substitute the benzothiazole/light sensitive compound of Stevens et al. and Scheler for the TRACER of Luthra et al. to generate a <sup>18</sup>F radiolabelled benzothiazole (derivative) via the polymer-bound/solid support of Luthra et al. as Stevens et al. teaches of <sup>18</sup>F-substituted benzothiazoles. Luthra et al. and Stevens both teach of <sup>18</sup>F radiolabelled radiopharmaceutical agents for use in PET. It would have been predictable and advantageous to use the polymer-bound/solid support of Luthra et al. to radiolabel benzothiazoles with <sup>18</sup>F to avoid time consuming purification steps and allow for ease of production and greater throughput (Luthra et al.; p1, [0003]). Also, it would have been obvious to one ordinarily skilled in the art to attach a benzothiazole (derivative) to the polystyrene solid support (Luthra et al.) as Scheler also teaches that benzothiazole may be linked to a polystyrene solid support via a coupler.

Art Unit: 1618

## Conclusion

No claims are allowed at this time.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELISSA PERREIRA whose telephone number is (571)272-1354. The examiner can normally be reached on 9am-5pm M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael G. Hartley/ Supervisory Patent Examiner, Art Unit 1618

/Melissa Perreira/ Examiner, Art Unit 1618